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Early dosing practices and effectiveness of recombinant human eryth.
ropoietin. In a national longitudinal-cohort study of 59,462 end-stage
renal disease (ESRD) patients, we examined dosing and effectiveness of
erythropoietin (EPO) during the first year of its use in clinical practice
(July 1989 through June 1990). In unadjusted and multivariate analyses
of Medicare claims data, the mean dose of EPO prescribed was:
relatively small and similar for initial and maintenance therapy, 2752
(95% confidence interval 2740 to 2764) and 2668 (95% confidence
interval 2654 to 2682) units, respectively; lower when initial therapy
was started later (591 units lower in September 1989 and 760 units lower
in November 1989 vs. July 1989, P < 0.0001); tower by 135 units during
initial therapy and by 116 units during maintenance therapy for females
(who weigh less) compared to males (P < 0.001); and lower by 400 units
for patients treated in for-profit versus not-for-profit centers. In multi-
variate analysis: hematocrit response was less and mean maintenance
dose was 298 units and 621 units greater for patients whose ESRD was
due to multiple myeloma and sickle cell disease, respectively, com-
pared to those with hypertension-related ESRD (P < 0.01); and
hematocrit response was logarithmically related to dose [hematocrit =
0.97 In (dose), P < 0.0001]. Forty-four percent of patients had a
hematocnt  30 after four months of therapy. The percent of patients
transfused during three monlh periods before and after therapy de-
creased from 20% to 5%, respectively (P < 0.0001). Our results suggest
that dosing practices were substantially modified to prescription of
smaller and more fixed doses over time, due to the interplay of clinical
concerns and economic forces. They also suggest that the effectiveness
of EPO in increasing hematocrit levels and reducing transfusion use in
routine clinical practice was less than anticipated based on the experi-
ence in clinical trials in part as a result of dosing practices.
Human recombinant erythropoietin (EPO) was approved by
the US Food and Drug Administration (FDA) in June of 1989
for use in the treatment of the anemia of End-stage renal disease
(ESRD). The Medicare program began paying for EPO in July
1989. In clinical trials therapy with EPO increased hematocrit in
a dose-dependent fashion, eliminated the need for blood trans-
fusions, increased exercise capacity and improved many dimen-
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sions of quality of life in hemodialysis patients with anemia
[1—7]. As a result, expectations of the effectiveness of this
expensive (approximate annual cost per patient of $6000) ther-
apy were high [8—10].
When a new drug, such as EPO, is introduced into clinical
practice there can be uncertainty about how it will be pre-
scribed. In large part this reflects the larger number of physi-
cians, practicing at health care institutions throughout the US,
that will prescribe the drug. Furthermore, potential side effects
may not be recognized or their association proven, new knowl-
edge regarding the drug may emerge after the early trials have
been completed, and new information may take time to be
disseminated [11—16]. Third party payment policies also have
the potential to influence treatment patterns.
In addition, it is often uncertain whether a new drug, with
demonstrated efficacy in the selected patient samples enrolled
in clinical trials, will be as effective when used in a more general
population of patients. For example, the phase III clinical trials
of EPO excluded hemodialysis patients with systemic illnesses
[2]. The phase IV multicenter National Cooperative rHuEPO
Study, designed to include a population of patients and treat-
ment centers representative of the US [17] enrolled 447 patients
at 68 centers out of a potential 100,000 US patients receiving
treatment at over 2000 Medicare-certified dialysis centers [17].
Most patients (58%) had already begun therapy with EPO at
enrollment precluding examination of dosing, effectiveness and
dose-response in the initial stage of therapy. Females and
Blacks were over-represented, and patients less than 18 years
of age were excluded.
Prescribing practices of ESRD providers during the early
period of medication use have not been studied comprehen-
sively. The use of Medicare claims data to monitor practice
patterns and measure the effectiveness of interventions in usual
or routine clinical practice settings has been advocated [18—191
but not applied to the examination of continuous drug therapy.
Medicare data almost completely represent the ESRD popula-
tion, since Medicare covers approximately 93% of all ESRD
patients in the US [20]. With this in mind, we used Medicare
claims data to conduct a national study of EPO dosing and
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effectiveness in dialysis patients during the first year following
FDA approval of EPO therapy.
Methods
Study design
We conducted a longitudinal-cohort study of ESRD patients
who received EPO during the first year after FDA approval and
Medicare coverage of EPO. Patients were included if they had
been enrolled in the Medicare ESRD program (entitled to
Medicare Part B services) at any time between July 1, 1989 and
June 30, 1990 (the study period), had not received a kidney
transplant, and had a claim for EPO payment submitted to
Medicare by a Medicare-certified ESRD provider.
Data sources
Data on patient characteristics, including date of enrollment
in the ESRD program, age, gender, race (Black, White, other),
assigned cause of ESRD, duration of ESRD, dialysis type
(hemodialysis, peritoneal) and characteristics of the treatment
facility at which the patients received care, such as ownership
(for-profit vs. non-profit), treatment facility setting (hospital-
based vs. freestanding) and HCFA renal network membership
(an 18 category geographic designator), were obtained from the
ESRD Program Management and Medical Information System
(PMMIS) [21]. Using ICD-9-CM codes, assigned causes of
ESRD were grouped into 11 categories: hypertension (401, 403,
404), diabetes mellitus (250), glomerulonephritis (acute and
chronic 580, 581, 582.1, 583), infections (such as, chronic
pyelonephritis, 590), polycystic disease (753.1), lupus (695.4,
710), multiple myeloma (203), congenital (such as, anomalies of
the kidney and urinary tract except polycystic disease 753.0,
753.2, 753.3, 759.8), metabolic (such as, gouty nephropathy
274.1 and amyloidosis 277.3), sickle cell anemia (282.6), and all
other diagnoses.
Data on the dose of EPO administered and hematocrit level
were obtained from claims submitted by treatment facilities to
Medicare on behalf of ESRD patients. The Health Care Financ-
ing Administration (HCFA) required treatment facilities to
submit the most recent dose of EPO administered, the most
recent hematocrit recorded, and the number of times EPO was
administered during the period of service defined by the claim.
The period of service covered by 99% of the individual EPO
claims was one calendar month or less. Data on blood transfu-
sions administered by outpatient dialysis facilities to ESRD
patients were obtained from quarterly dialysis billing records
contained in the PMMIS.
For each patient meeting the inclusion criteria, we con-
structed a chronological record of EPO treatment which con-
tained the last administered dose and the last recorded hemat-
ocrit for each month of EPO therapy up to a maximum of 12
months. A 12 month record indicated that EPO therapy began
in July 1989 and continued uninterrupted until June 1990.
Shorter records indicated that either the patient began EPO
therapy in the first month of the study period but did not
continue therapy throughout the study period or that the patient
began therapy in a later month and may or may not have
continued until the end of the study period. Because EPO use
was determined through Medicare claims, we could not be
certain whether patients received EPO during their first three
months of ESRD treatment prior to their enrollment in the
Medicare program or before they received their first treatment
(that is, pre-ESRD). In order to explore the potential effect of
underreporting, we examined the number of missing values and
characteristics associated with such values in the first and
fourth months of therapy, months from which we used data to
examine dose-responsiveness of EPO.
Dosing analyses
We defined twelve cohorts of patients who received EPO,
according to the calendar month during the study period in
which they started therapy. To investigate changes in dosing
patterns over time, we compared the mean dose (95% confi-
dence interval, CI) of EPO prescribed during the initial or a
subsequent month (fourth month) of treatment between the
cohorts. To compare changes in dosing from initial to mainte-
nance therapy between those who started EPO in earlier versus
later months, for three cohorts we compared the mean dose
(95% CI) of EPO prescribed during the initial month with that of
a subsequent month (fourth month) of treatment. We examined
the relationship between calendar month and dose, gender (as a
proxy for weight) and dose, between assigned cause of ESRD
and dose and between ownership of treatment facility and dose
using both bivariate and multivariate (multiple regression) anal-
yses. Variables (except the one of interest) controlled for in the
multivariate analysis included hematocrit, number of EPO
administrations, age, gender, race, duration of ESRD, dialysis
type, renal network of the provider, provider profit-status and
treatment-facility setting. ESRD due to hypertension was used
as the reference group for comparison of ESRD cause in our
multivariate analyses, since this was the largest group among
those patients receiving EPO.
Hematocrit analyses
We examined the mean change in hematocrit (95% CI)
between the first and the fourth month of EPO use for nine
cohorts which had at least four months of data (cohorts begin-
fling EPO therapy during one of the first 9 months). A change
over four months was used as an indicator of response, since in
clinical trials patient's hematocrit had risen substantially and
larger initial doses had been reduced to lower maintenance
doses over this period [2]. We compared the average change in
hematocrit between the first and the fourth month of EPO use
according to patient characteristics. We used multiple regres-
sion analysis to examine the relationship between the change in
hematocrit (from the first to the fourth month of EPO use) and
average dose (first through fourth month), and between the
change in hematocrit (from the first to the fourth month of EPO
use) and assigned cause of ESRD, while adjusting for other
patient characteristics, such as age, gender, race, cause of
ESRD, in (dose), in (number of administrations), duration of
ESRD, dialysis type, renal network of the provider, provider
profit status and treatment facility setting, except the charac-
teristic of interest.
Transfusion analyses
Since blood transfusion data are available on a quarterly as
opposed to a monthly basis, we constructed a cohort of patients
who began EPO therapy during the first month (July, October
or January) in one of three successive quarters (third quarter of
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1989, fourth quarter of 1989, or first quarter of 1990, respec-
tively) during the study period. We also required that these
patients be alive for six months (two quarters) before and six
months after EPO was first administered. For this cohort we
examined the percent of patients receiving transfusions, the
total number of blood units administered and the mean number
of blood units (95% CI) among patients receiving blood before
or after EPO was first prescribed. We also examined the change
in hematocrit from the first to the fourth month of treatment
among four groups of patients, defined by transfusion use
before and after the start EPO therapy, in both unadjusted and
multivariate analyses controlling for dose of EPO, frequency of
EPO administration and other patient characteristics.
Results
Patient selection and characteristics
Between July 1, 1989 and June 30, 1990 (the study period),
63,727 patients who were enrolled in the ESRD program and
had never received a kidney transplant were treated with EPO
during at least one month. For 59,462 (93%) the dose of EPO
administered during the first month of EPO therapy was re-
corded and for 58,672 (92%) hematocrit data during the first
month of therapy was recorded. The proportion of patients with
and without first month dose or hematocrit data was indepen-
dent of the other study variables including age, gender, race,
underlying cause of ESRD, duration of ESRD and dialysis type.
There was a difference in the proportion of patients with and
without dosing or hematocrit data according to renal network.
Forty-five percent of all missing dosage information and 46% of
all missing hematocrit data were from one of eighteen network
areas. In addition, the percent of patients with no dose or
hematocrit data in the fourth month and the distribution of
missing versus non-missing data by patient characteristics were
similar to those based on first month data. Patients with missing
values in a given month were excluded from the analyses for
that month because there appeared to be no systematic bias in
the data according to patient characteristics.
Table 1 shows the characteristics of patients who received
EPO for at least one month during the study period and had
dose data for the first month of treatment (N 59,462). The
number of patients receiving EPO for more than one month
declined, because many patients (cohorts) started EPO toward
the end of the study period and some patients either died or
discontinued their therapy. Patient attrition, adjusted for death
and the initiation of EPO therapy during the later months of the
study for the twelve combined cohorts, was 4.8% at two
months, 8.3% at three months and 11.3% at four months.
Dosing of EPO
For the 59,462 patients with observations on dosage during
the first month of EPO therapy, the mean (95% CI) dose in the
first month of EPO therapy was 2752 (95% CI 2740 to 2764)
units. EPO was administered an average of 7.13 (95% CI 7.09 to
7.17) times per patient during the first month of therapy. The
exact dosing schedule for this month is indeterminable since
many patients did not start therapy on the first day of the
month. In addition, some patients were undergoing peritoneal
or home dialysis. The mean dose was 2668 units (95% CI 2654
to 2682) in the fourth month of therapy for the 40,891 patients
Table 1. Characteristics of ESRD patients treated with
erythropoietin during at least one month between July 1, 1989
through June 30, 1990 (N = 59; 462k)
Number %Characteristic
Age years
0—19
20—34
35—49
50—64
65 +
Gender
Male
Female
299 0.5
3,899 6.6
8,585 14.4
17,607 29.6
29,072 48.9
28,263 47.5
31,199 52.5
35,869 60.3
20,586 34.6
3,007 5.1
47,829 80.4
8,580 14.4
3,053 0.05
17,275 31.2
16,655 28.0
10,111 18.2
1,971 3.6
1,818 3.3
1,021 1.8
379 0.7
364 0.7
258 0.5
71 0.1
5,531 10.0
4,008 6.7
55,246 96.9
4,206 7.1
11 0.1
59,462 100.0
2 52,960 89.1
3 46,579 78.3
4 40,891 68.8
5 34,923 58.7
6 29,287 49.2
7 23,692 39.8
8 18,493 31.1
9 13,332 22.4
10 8,407 14.1
11 3,793 6.4
12 907 1.5
Abbreviation is: ESRD, End-stage renal disease.
Patients with dose data present in first month of EPO therapy N =
59,462
alive and still remaining on EPO. The average number of EPO
administrations rose to 10.65 (95% CI 10.58 to 10.72) per month
by the fourth month of treatment, as more patients were under
chronic therapy. The modal (most common) number of admin-
istrations for all four months was 13 or three times per week.
The dose of EPO and magnitude of reduction from initial
phases of dosing to maintenance phases was associated with the
calendar month in which therapy began (Fig. 1). For 2619
patients who began in July 1989, the mean initial dose was 3576
(95% CI 3498 to 3654) units and fell to 3152 (95% CI 3066 to
3238) units in the fourth month, with a mean reduction in dose
of 12.1%. In contrast, the mean first month dose for the
Race
White
Black
Other
Duration of ESRD years
0-4
5—9
10
Cause of ESRD
Hypertension
Diabetes
Glomerulonephritis
Infections
Polycystic
Lupus
Multiple myeloma
Congenital
Metabolic
Sickle cell
All other
Unknown
Dialysis type
Hemodialysis
Pentoneal
Unknown
Duration of treatment months
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3700
3500
3300
3100
2900
2700
2500
period.
0
N0
—0 0—0 0_0
Table 2. Results of multivariate model for dose (units) of EPO in
fourth month of use
Variable
Reference
groupa
Adjusted
estimat&' P value
Calendar month
October 1989
November 1989 —371 <0.0001
January 1990 —477 <0.0001
March 1990 —514 <0.0001
June 1990 —520 <00001
Gender
Male
Female —116 <0.0001
Cause of ESRD
Hypertension
Diabetes +15 0.41
Glomerulonephritis +38 0.06
Polycystic —76 0.07
Multiple myeloma +298 0.001
Congenital —150 0.08
Sickle cell anemia +621 0.002
U)
C
C
a)
U)0
0 1 2 3 4 5 6 7 8 9 10 11 12
Month of EPO use
Fig. 1. Dose (mean) of erythropoietin over lime in cohorts of endstage
rena! disease patients according to calendar month in which the drug
was first administered. N = 2619 for the July 1989 cohort (0), 6896 for
the September 1989 cohort (A), and 5748 for the November 1989 cohort
(•).
September 1989 (6896 patients) and November 1989 cohorts
(5748 patients) was considerably lower, with a lower mean
reduction in dose of 7.1% over four months for patients in the
September 1989 cohort, and 2.5% for patients in the November
1989 cohort.
Because characteristics of the population receiving EPO
could change over time and confound these results, we con-
trolled in multivariate analysis for hematocrit, number of EPO
administrations, age, gender, race, duration of ESRD, dialysis
type, renal network of provider, and profit status and affiliation
of the provider. This analysis confirmed that the mean dose of
EPO was lower during the first month of treatment for patients
starting therapy in August, September, October or November
1989 than for patients starting therapy in July 1989. Mean dose
was also significantly lower in the fourth month of EPO therapy
in cohorts which began EPO therapy later in the study period
(Table 2). A separate person-level, longitudinal analysis indi-
cated there was a greater than 5% titration of dose from the first
to fourth month of therapy in 45% of patients overall. However,
titration was less the later patients began therapy in the study
Dosing and patient characteristics
In bivariate analysis, female gender and underlying cause of
renal failure were associated with significant differences in EPO
dosage. Mean dose during the first month of EPO treatment was
2690 (95% CI 2674 to 2706) units for females compared to 2819
(95% CI 2801 to 2837) units for males. Mean dose during the
fourth month of EPO therapy was 2615 (95% CI 2596 to 2634)
units for females compared to 2731 (95% CI 2712 to 275) units
for males. Mean dose during the first month of EPO therapy
was 3056 (95% CI 2904 to 3208) units for patients with multiple
myeloma as an assigned cause of ESRD and 2970 (95% CI 2592
to 3348) units for their counterparts with sickle cell disease,
compared to 2688 (95% CI 2667 to 2709) units for those with
hypertension as a assigned cause of ESRD. Mean dose during
the fourth month of EPO therapy was 3038 (95% CI 2838 to
3237) units for patients with multiple niyeloma as the assigned
cause of ESRD and 3418 (95% CI 2683 to 3613) units for their
a The unadjusted estimates (95% confidence limit) for the reference
groups were as follows: calendar month (October 1989), 2650 units
(2617 to 2682); gender (male), 2731 (2712 to 2750) units; and cause of
ESRD (hypertension) 2645 units (2620 to 2670).
b Coefficient (representing deviation from reference group) from
multiple regression analysis in which dose was adjusted for several
characteristics (hematocrit, number of EPO administrations, age, gen-
der, race, duration of ESRD, cause of ESRD, dialysis type, renal
network of provider and profit status and treatment setting of provider)
except the variable of interest.
counterparts with sickle cell disease compared to 2645 (95% CI
2620 to 2670) units for patients with hypertension as the
assigned cause of ESRD.
The results from bivariate analysis showing higher doses for
males compared to females and for patients with multiple
myeloma and sickle cell disease as an assigned cause of ESRD
compared to their counterparts with hypertension (the refer-
ence group) remained statistically significant in multivariate
analysis, controlling for age, gender, race, hematocrit and
number of EPO administrations in the month, duration of
ESRD, dialysis type, renal network of the patient's provider
and ownership type (Table 2). Multivariate analysis of the mean
dose of EPO during the first month of therapy showed similar
results, except that the higher dose (by 209 units) for patients
with sickle cell disease compared to those with hypertension
(the reference group) was not statistically significant (P 0.22).
Patients with other causes of ESRD (such as, diabetes mellitus,
glomerulonephritis and polycystic kidney disease) had doses in
both the first and the fourth months of use that were less than
100 units different or that were not statistically significantly
different from those with hypertension as the cause of ESRD. In
multivariate analysis controlling for patient characteristics, the
EPO dose was 400 units less for patients treated in for-profit
compared to not-for-profit dialysis centers. There was no sig-
nificant association between age, race or year of onset of ESRD
and dose of EPO.
Hematocrit response
Mean hematocrit rose from 26.7% (95% CI 26.65 to 26.74)
during the first month of EPO treatment to a peak of 28.9%
(95% CI 28.85 to 28.95) during the fourth month of EPO
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treatment among patients with hematocrit data in the first and
fourth months. The mean change in hematocrit from the first to
the fourth month of EPO use was +2.47 (95% CI 2.41 to 2.53)
percentage points. The mean change in hematocrit was + 1.57
percentage points for 210 patients with multiple myeloma, as
the cause of their ESRD and was —3.03 percentage points for 48
patients with sickle cell disease as the cause of their ESRD.
Figure 2A shows mean hematocrit over time for cohorts of
patients beginning EPO therapy in July, September or Novem-
ber of 1989. The average first month hematocrit was slightly
lower for the July 1989 cohort, possibly explaining their higher
starting dose and also suggesting that the most severely anemic
patients were the first patients to be treated with EPO. In
contrast to dosing practices, patterns of hematocrit increase
varied according to calendar month of first EPO therapy, but
probably not substantially (that is clinically important). Twen-
ty-four percent of patients had a hematocrit greater than or
equal to 30 in the first month of EPO use compared to 44% in
the fourth month of EPO therapy (Fig. 2B). Fourteen percent of
patients had a hematocrit less than 22% in the first month of
EPO therapy whereas only 4.3% had a hematocrit less than 22%
in the fourth month of EPO therapy.
In bivariate and multivariate analyses, we examined the
association between the change in hematocrit from the first to
the fourth month of EPO therapy and dose. Figure 3 shows the
unadjusted association between the change in hematocrit and
average doses in the first to the fourth month. The relationship
is non-linear and resembles a logarithmic function in which the
change in hematocrit is related to the logarithm of the dose; that
is, change in % hematocrit = f [ln (dose)j. The plateau at higher
doses may indicate a group of patients which was relatively
resistant to EPO. In multivariate analysis, adjusting for patient
characteristics including the frequency of administrations, there
was a significant association (P < 0.0001) between change in
hematocrit (first to fourth month) and the logarithm of average
(first to fourth month) dose, but the magnitude of this associa-
tion was small, a +0.97 increase in percent hematocrit for each
unit increase in in dose of EPO. Change in hematocrit was also
0
>0.5—1.5 >1.5—2.5 >2.5—3.5 >3.5—4.5 >4.5—5.5 >5.5—6.5 6.5
Dose of EPO, thousands of units
Fig. 3. Relationship of change in hematocrit to EPO dose: unadjusted
change in hematocrit and 95% confidence interval from the first to the
fourth month of EPO use as a function of average dose (first through
fourth month) of EPO (N = 39,183). The average dose administered was
>500 to 1,500 units for 3265 patients, >1,500 to 2,500 units for 18082
patients, >2,500 to 3,500 units for 10,594 patients, >3,500 to 4,500 units
for 5680 patients, >4,500 to 5,000 for 904 patients, >5,500 to 6,500 units
for 338 patients and >6,500 units for 316 patients. Four patients with
doses less than 500 units were excluded.
positively associated (P < 0.0001) with the number of EPO
administrations per month [change in % hematocrit = 1.1 x ln
(number of administrations/month)]. Patients with multiple my-
eloma and sickle cell disease as the cause of ESRD had smaller
increases in hematocrit between the first and fourth month,
—0.76 and —5.7, respectively, relative to patients with hyper-
tension (the reference group) as the cause of ESRD, adjusting
for dose and other characteristics. Congenital (non-polycystic)
disease as the assigned cause of ESRD was associated with a
significantly (P < 0.001) greater change in hematocrit (+ 1.28)
between the first and fourth month of EPO use compared to
hypertension (the reference group) as the cause of ESRD.
There was no significant difference in change in hematocrit
BA
30 50
Cl)
29 40
28 30
27 20
26 i 10
25 I I I I I I I I I 00123456789101112
Month of EPO use Month of EPO use
Fig. 2A. Hematocrit (mean) over time in cohorts of end-stage renal disease patients following administration of e,ythropoietin according to
calendar month in which the drug was first administered. N = 2619 for the July 1989 cohort (0), 6896 for the September 1989 cohort (A), and 5748
for the November 1989 cohort (U). B Distributions of the percent of end-stage renal disease patients with hematocrit  30% (open bars) and < 22%
(solid bars) for end-stage renal disease patients following administration of erythropoietin. See Table 1 for total number of patients for each month.
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between the first and fourth month according to patient age,
gender, or race. For the multiple regression model, the adjusted
r square was 0.01 and F value 11.7 (P < 0.0001).
Transfusion therapy
There were 13,481 patients who began EPO therapy in July
1989, October 1989 or January 1990, and who had been enrolled
in the ESRD program for at least six months prior to the first
month of EPO therapy. Figure 4 shows that 20% of these
patients were transfused in outpatient dialysis facilities during
each of the two quarters immediately preceding the initiation of
EPO therapy (Qtr —2 and Qtr —1), compared to 11.2% during
the first quarter of EPO therapy (Qtr + 1) and 5.3% during the
second quarter of EPO therapy (Qtr +2).
Comparison of blood use in the three months immediately
prior to the initiation of EPO therapy to blood use in the four to
six months following therapy (after the rise in and plateau of
hematocrit) showed that of the 2701 patients who were trans-
fused before EPO therapy, 14.3% also received blood after EPO
therapy compared to 3% of the 10,780 patients who did not
receive blood prior to therapy; relative risk (95% CI) of receiv-
ing blood after EPO therapy according to transfusion use
(yes/no) before EPO therapy = 4.7 (4.6 to 4.8). The mean (95%
CI)) number of units transfused among these patients who
received blood before EPO therapy was 4.3 (4.0 to 4.6) units
compared to 3.4 (3.0 to 3.8) units among patients transfused
after EPO therapy. The mean unadjusted change in percent
hematocnt from the first to the fourth month of EPO therapy
was approximately the same for patient groups who did not
receive transfusions after EPO therapy; +2.6 and +3.0 percent-
age points for those receiving blood before and after EPO
therapy, respectively. However, the change in hematocrit was
Discussion
The results of our national study of EPO dosing and effec-
tiveness reflect many factors in clinical nephrology which
influence decision making and patient outcomes, including
economic incentives, the heterogeneity of dialysis patients and
providers and the quality of patient care. Our findings suggest
that, in contrast to the timeliness with which patients received
treatment (indicated by the impressive number of patients
receiving therapy during the first year of availability of EPO)
[221, patients may not have been dosed optimally. The average
first month dose per administration of EPO in our study (2690
units) was less than anticipated based on the product labeling
which recommended a starting dose of 50 to 100 units per kg,
the National Kidney Foundation recommendation of doses as
high as 150 units per kg [8] and the doses used in early clinical
trials, in which up to 150 units per kg of body weight was
administered as an initial intravenous dose. If one assumes that
the average weight of an ESRD patient is between 60 and 80
kilograms, then at a recommended amount of 50 units per kg,
the recommended dose would be 3000 to 4000 units per admin-
istration. Total dose at a recommended amount of 100 units per
kilogram would be substantially higher, 6000 to 8000 units. In
contrast to doses administered, the frequency of administration
followed recommendations more closely as indicated by the
average number of times EPO was administered each month.
EPO maintenance doses were less than starting doses in
phase III trials and product labeling recommended high starting
doses and lower maintenance doses. In our study there was a
progressively smaller difference between starting doses and
maintenance doses over time, indicating that physicians' dosing
practices were modified during the course of the first year of
EPO use. Some patients first treated in July 1989, when
observed doses were high, may have been enrolled in clinical
trials, but their numbers were likely to be small. Although doses
were small, the differences in dosing according to gender and
ESRD cause indicate that clinical considerations, in part,
influenced relative dosing.
There are several possible reasons why dosing was lower
than recommended dosing and why change occurred in the
early months of EPO use in routine clinical practice. First,
although knowledge regarding the effectiveness of EPO may
have been adequately communicated to physicians through
dissemination efforts such as scientific and educational litera-
ture and programs, this may not have been true for information
on dosing levels and hematocrit targets. The higher doses
administered in patients treated shortly after EPO became
available (for example, July 1989) may reflect care provided by
nephrologists who were more knowledgeable about dosing as a
result of participation in clinical trials. Second, the target
hematocrit of 30 to 33% recommended in the manufacturer's
product labeling was different than the target of 35% used in the
early clinical trials. This lower target hematocrit may have
arisen from FDA requirements. Also, nephrologists may have
believed that the dose needed to achieve the lower, manufac-
turer established target would be less than that used in the initial
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clinical trials. Third, some Medicare intermediaries instituted
rules that EPO would not be reimbursed without appropriate
medical justification if a patient's hematocrit exceeded 35 to
36%. This may have influenced more conservative dosing.
Fourth, physicians may have thought it was safer to raise
hematocrit more slowly, and thus started at smaller doses that
would be considered maintenance rather than starting doses.
Possibly, physicians anticipated that side effects such as hyper-
tension would occur less often, would be less severe and would
be more easily managed with lower starting doses [23—25].
Furthermore, early concern about whether EPO therapy results
in an increased incidence of seizures or thrombosis of vascular
access used for hemodialysis [2, 3, 26, 27] may have led to a
more conservative dosing approach. Monitoring of iron stores
and replacement might also be more carefully achieved with a
slower rise in hematocrit [28]. Filth, nephrologists may have
believed that the incremental benefits for dialysis patients (in
terms of exercise tolerance, quality of life, and possibly avoided
cardiovascular morbidity) of increasing hematocrits beyond 28
to 30% were small.
Finally, and extremely important, since Medicare paid a fixed
amount for EPO, $40 per administration for up to 10,000 units,
smaller doses would be associated with higher revenue over
expense for EPO and doses above approximately 4000 units
would be associated with lower revenue than expense. The
balance between the payment amount for EPO and a dialysis
provider's true cost of administering EPO (that is, profit or loss)
could have influenced dosing practices. Thus, the lower doses
observed over time could, in part, reflect growing provider
awareness of the financial advantage of using a lower dose of
EPO and the disadvantage of using a dose that costs more than
the amount being reimbursed. The lower doses observed in
for-profit compared to not-for-profit dialysis centers suggests
that the financial incentive was important. Effective January 1,
1991, the payment mechanism was changed to $11 per admin-
istration of 1000 units of EPO to more resemble per unit (of
product) payment reflecting, in part, the financial incentive (to
use less drug) that is inherent in a per treatment, fixed payment
method. Our results document the remarkable speed with
which change in dosing practices occurred within the US ESRD
provider community and illustrate the uncertainty in predicting
prescribing behavior when a new drug becomes available in
medical practice in the US, due to the complex interplay of
economic forces and clinical considerations.
Our results also indicate that EPO increases hematocrit for a
large number of dialysis patients. However, in our study, only
40% of those treated achieved the expected target hematocrit of
30%, set by the manufacturer, after at least four months of
therapy. The Phase IV multicenter National Cooperative rHu
Erthropoietin Study showed that 57.5% of 94 enrolled ESRD
patients achieved a hematocrit level greater than 30.0%, with a
mean hematocrit of 30.6% after three months of EPO therapy
[17]. While our results are slightly different, they are similar in
that lower doses of EPO were administered and lower hemat-
ocrits were observed than those observed in earlier phase III
clinical trials.
The first, and most likely, reason that relatively low hemat-
ocrits were achieved is the fact that lower than expected doses
of EPO were administered. A second concern, suggested by our
results, is that the low hematocrits may have arisen, in part,
from extrinsic factors that could modulate change in hemat-
ocrit. We observed a logarithmic relationship between the dose
of EPO administered and change in hematocrit. A non-linear,
but not logarithmic, dose-response relationship of EPO has
been reported [29]. The magnitude of the response we observed
appears smaller than that reported in an early clinical trial of
EPO in four to five ESRD patients who received either 15, 50,
150 or 500 units per kilogram of EPO and had adequate iron
stores [1]. Based on the results of this trial, for starting doses in
the range of 50 units per kilogram or 3500 units per administra-
tion for a 70 kilogram patient (without systemic illnesses such as
diabetes or hemolysis), a 1000 unit increase in starting dose
would be expected to result in an absolute increase of approx-
imately 3% in hematocrit over three to four months. In addition,
another report on 37 hemodialysis patients has shown that a
relatively small dose (3000 units) of EPO administered three
times a week increased mean hematocrit from 25.2% to 32.2%
over four months [25]. We observed smaller absolute increases
in hematocrit, 0.50%, 0.33% and 0.24% per 1000 unit increase in
dose, for doses in the range of 1500, 2500 and 3500, respec-
tively.
The weaker relationship of change in hematocrit to dose,
observed in our study, could have arisen from the lack of a
more precise accounting of patient weight (other than gender),
the fact that the baseline hematocrits we used were not neces-
sarily obtained prior to the start of EPO therapy, lack of
information on patients' iron status or the influence of modu-
lating factors on hematocrit response in the larger population of
ESRD patients and providers. Dose explained only a minimal
amount of the variability in the change in hematocrit between
the first and fourth month of EPO therapy, suggesting that
factors we could not isolate may be more important determi-
nants of hematocrit changes in the general US ESRD popula-
tion. Most importantly, uncorrected iron deficiency has been
implicated as the most common contributor to an attenuated
response to EPO [26, 30, 32, 33]. Less commonly, other
co-morbidity such as infection, inflammation, hyperparathy-
roidism, malignancy and aluminum excess can influence re-
sponsiveness to EPO. Unfortunately, we did not have a entire
accounting of patients' comorbidity. The finding that patients
with multiple myeloma and sickle cell disease required larger
doses is consistent with the expected and observed diminished
hematocrit response in patients with a disease which potentially
affects red blood cell production or destruction. The meager
changes in hematocrit observed in patients who require versus
do not require transfusions after EPO therapy suggest that EPO
may have been ineffective in a small number (5%) of patients.
We do not know whether these patients had blood loss or
increased destruction or decreased production of erythrocytes.
Another explanation for our findings is that more meticulous
attention may have been paid to the care that EPO recipients
were receiving in early clinical trials than in routine clinical
practice. Identification and treatment of iron deficiency which
affects EPO response and patient compliance with physician's
recommendations for iron supplementation may not be optimal
in clinical practice. It is also possible that adequacy of dialysis,
which can affect hematocrit, may modulate response. Further
attention should be directed at confirming or rejecting these
possible reasons for our observations.
Although therapy with EPO was associated with a dramatic
1132 Powe et a!: rHuEPO dosing and effectiveness
decline in the number of patients who received outpatient blood
transfusions in dialysis centers, EPO did not entirely obviate
the need for outpatient transfusions as reported in clinical trials,
Twenty percent of patients received transfusions in each of the
two quarters prior to the initiation of EPO therapy and 5.3% in
the second quarter after therapy. Blood use prior to EPO
therapy was associated with a nearly five times higher risk of
blood use after EPO therapy. The residual need for transfusions
might arise from low doses and the resultant low hematocrits or
possibly other medical events (such as, surgery, gastrointestinal
hemorrhage, bleeding from vascular access sites) in ESRD
patients which require more urgent treatment of anemia than
EPO therapy can provide. If hematocrits had been increased to
the target level of 35%, there might have been less need for
transfusions regardless of other medical events contributing to
anemia. It is also possible that the criteria (or thresholds) that
individual physicians use in deciding when to administer trans-
fusions in routine clinical practice, which we could not assess,
are different from those used in clinical trials.
Even with the exclusion of transfusions that are administered
in a hospital setting, the transfusion rate among those receiving
blood prior to the availability of EPO was approximately one
unit per patient, per month. This is more than twice the rate
observed in one multicenter clinical trial [2]. This higher rate
may reflect the fact that patients who received EPO early (that
is, in the first year of its availability) had more severe anemia.
Our finding that the baseline hematocrits were lowest for
patients who began EPO in July 1989 is consistent with this
possibility. In addition, more patients with comorbid condi-
tions, such as chronic gastrointestinal bleeding, may have been
excluded from the clinical trial but included in our population.
There are possible limitations of our study. Data on whether
EPO was administered subcutaneously versus intravenously
were not available from Medicare claims. Smaller doses may be
required when EPO is administered subcutaneously [29]; how-
ever, in the early period of use intravenously administered
doses were probably most common [17]. In addition, our results
are comparable to those in a smaller cohort of 94 patients new
to EPO therapy for whom doses during the first, second and
third months of treatment averaged 2300 units, 2484 units and
2216 units, respectively [17] and to those doses documented in
another earlier report [34].
Our study was limited by the lack of data on patient weight,
despite the fact that we adjusted for gender in our multivariate
analyses, the measurement of only one dose and hematocrit per
month for each patient, the possibility that a small proportion of
patients may have received EPO prior to Medicare coverage,
and the lack of data on EPO or transfusions that are adminis-
tered during hospital inpatient stays (such as, in association
with surgery). In addition, although a validation study of
Medicare PMMIS data has shown overall correspondence of
91% between Medicare data items and medical records [35]
dose and hematocrit data are those reported by treatment
centers through the claims submission process rather than those
abstracted from medical records which have undergone formal
reliability testing. While a study based on Medicare claims data
has limitations, such as a finite range of desired variables, it also
has distinct advantages including data on a variety of patients
treated in nephrologists' practices throughout the US that may
be more representative than that obtained at selected medical
centers.
In summary, our study suggests that dosing practices of EPO
in the US changed rapidly during the early period of use and did
not follow promulgated recommendations. It illustrates how
economic forces and a variety of clinical factors could affect
nephrologists' prescription of a new therapy. The results also
indicate that EPO was effective in increasing hematocrit and
reducing transfusions in routine clinical practice. However,
effectiveness in routine clinical practice appears limited due to
administration of low doses and perhaps to reduced hematocrit
targets. EPO is the first recombinant biotechnology drug to be
covered by Medicare for outpatient use. Greater attention to
factors that influence physician practice is necessary to assure
appropriate prescribing and realization of the optimal health
benefits of high cost biotechnology.
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